Fighting malaria at the crossroads: The tools to battle the disease exist, but the lack of political will in developed nations jeopardizes their success

EMBO Reports

Volumn 5, Issue 9, 2004, Pages 847-851

  Rinaldi, Andrea ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; CHLOROQUINE; CHLORPHENOTANE; CHLORPROGUANIL PLUS DAPSONE; FANSIDAR; INSECTICIDE; MALARIA VACCINE;

ANOPHELES; ANTIBIOTIC RESISTANCE; ARTICLE; BED NET; DEVELOPED COUNTRY; DRUG CHOICE; DRUG COST; DRUG RESEARCH; DRUG SAFETY; ENDEMIC DISEASE; ENVIRONMENTAL SANITATION; ERADICATION THERAPY; FINANCIAL MANAGEMENT; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INSECT CONTROL; MALARIA; MORTALITY; NIGERIA; PARASITE VIRULENCE; PLASMODIUM FALCIPARUM; POLITICAL SYSTEM; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; ANIMAL; IMMUNOLOGY; PARASITOLOGY;

ANIMALS; ANOPHELES; DDT; HUMANS; MALARIA; MALARIA VACCINES;

EID: 16644378174     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/sj.embor.7400244     Document Type: Article

References (20)

1. Alloueche A et al (2004) A double-blind randomised comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children. Lancet 363: 1843-1848
2. Attaran A et al (2004) WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363: 237-240
3. Blandin S, Shiao S-H, Moita LF, Janse CJ, Waters AP, Kafatos FC, Levashina EA (2004) Complement-like protein TEP1 is a determinant of vectorial capacity in the malaria vector Anopheles gambiae. Cell 116: 661-670
4. Borovsky D (2003) Trypsin-modulating oostatic factor: A potential new larvicide for mosquito control. J Exp Biol 206: 3869-3875
5. Butler D (2004) Global fund changes tack on malaria therapy. Nature 429: 588
6. Fidock DA, Rosenthal PJ, Croft SL, Brun L, Nwaka S (2004) Antimalarial drug discovery: Efficacy models for compound screening. Nat Rev Drug Discov 3: 509-520
7. Gardner MJ et al (2002) Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419: 498-511
8. Hoffman SL et al (2002) Protection of humans against malaria by immunization with radiation attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155-1164
9. Holt RA et al (2002) The genome sequence of the malaria mosquito Anopheles gambiae. Science 298: 129-149
10. International Artemisinin Study Group (2004) Artesunate combinations for treatment of malaria: Meta-analysis. Lancet 363: 9-17
11. Mackinnon MJ, Read AF (2004) Immunity promotes virulence evolution in a malaria model. PLOS Biology 2: Doi: 10.1371/ journal.pbio.0020230
12. Molyneux DH, Nantulya VM (2004) Linking disease control programmes in rural Africa: A pro-poor strategy to reach Abuja targets and millennium development goals. BMJ 328: 1129-1132
13. Nirmala X, James AA (2003) Engineering Plasmodium-refractory phenotypes in mosquitoes. Trends Parasitol 19: 384-387
14. Osta MA, Christophides GK, Kafatos FC (2004) Effects of mosquito genes on Plasmodium development. Science 303: 2030-2032
15. Pearson H (2004) Vaccines may increase virulence. Nature Publishing Group Newsνature, 22 June. doi: 10.1038/news040621-3
16. Rosenberg T (2004) What the world needs now is DDT. New York Times 11 April
17. Webster D, Hill AVS (2003) Progress with new malaria vaccines. Bull World Health Organ 81: 902-909
18. Wendo C (2004) Uganda considers DDT to protect homes from malaria. Lancet 363: 1376
19. WHO, UNICEF (2003) The Africa Malaria Report 2003. WHO/CDS/MAL/ 2003.1093. World Health Organization, Geneva, Switzerland
20. Yamey G (2004) Roll Back Malaria: A failing global health campaign. BMJ 328: 1086-1087